[go: up one dir, main page]

WO2010040136A3 - Selection of hiv vaccine antigens by use of intrapatient sequence variation to identify mutations in the hiv envelope glycoprotein that affect the binding of broadly neutralizing antibodies - Google Patents

Selection of hiv vaccine antigens by use of intrapatient sequence variation to identify mutations in the hiv envelope glycoprotein that affect the binding of broadly neutralizing antibodies Download PDF

Info

Publication number
WO2010040136A3
WO2010040136A3 PCT/US2009/059583 US2009059583W WO2010040136A3 WO 2010040136 A3 WO2010040136 A3 WO 2010040136A3 US 2009059583 W US2009059583 W US 2009059583W WO 2010040136 A3 WO2010040136 A3 WO 2010040136A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
intrapatient
binding
affect
selection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/059583
Other languages
French (fr)
Other versions
WO2010040136A4 (en
WO2010040136A2 (en
Inventor
Phillip W. Berman
Sara O'rourke
William Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2010040136A2 publication Critical patent/WO2010040136A2/en
Publication of WO2010040136A3 publication Critical patent/WO2010040136A3/en
Publication of WO2010040136A4 publication Critical patent/WO2010040136A4/en
Priority to US13/079,472 priority Critical patent/US9782472B2/en
Anticipated expiration legal-status Critical
Priority to US15/694,388 priority patent/US10201603B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Selection of HIV vaccine antigens by use of intrapatient sequence variation to identify mutations in the HIV envelope glycoprotein that affect the binding of broadly neutralizing antibodies and polypeptides identified by these methods.
PCT/US2009/059583 2008-10-04 2009-10-05 Selection of hiv vaccine antigens by use of intrapatient sequence variation to identify mutations in the hiv envelope glycoprotein that affect the binding of broadly neutralizing antibodies Ceased WO2010040136A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/079,472 US9782472B2 (en) 2008-10-04 2011-04-04 Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
US15/694,388 US10201603B2 (en) 2008-10-04 2017-09-01 Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19511208P 2008-10-04 2008-10-04
US61/195,112 2008-10-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/053637 Continuation-In-Part WO2011050222A2 (en) 2008-10-04 2010-10-22 Therapeutic compositions that disrupt the hydrogen bonded ring structure in gp41 and methods for treating hiv

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/079,472 Continuation-In-Part US9782472B2 (en) 2008-10-04 2011-04-04 Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity

Publications (3)

Publication Number Publication Date
WO2010040136A2 WO2010040136A2 (en) 2010-04-08
WO2010040136A3 true WO2010040136A3 (en) 2010-07-15
WO2010040136A4 WO2010040136A4 (en) 2010-09-02

Family

ID=42074258

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/059583 Ceased WO2010040136A2 (en) 2008-10-04 2009-10-05 Selection of hiv vaccine antigens by use of intrapatient sequence variation to identify mutations in the hiv envelope glycoprotein that affect the binding of broadly neutralizing antibodies

Country Status (1)

Country Link
WO (1) WO2010040136A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150065381A1 (en) * 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP3303370A4 (en) * 2015-05-28 2019-03-13 Immunomedics, Inc. T20 CONSTRUCTION PRODUCTS FOR THERAPY AND / OR ANTI-HIV VACCINES (HUMAN IMMUNODEFICIENCY VIRUS)
CN107132066A (en) * 2017-04-28 2017-09-05 皖能马鞍山发电有限公司 A kind of coal sample takes control optimization method
CN114736930A (en) * 2022-04-30 2022-07-12 南京医科大学 A screening method and application of virus protein escape neutralizing antibody

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020077284A1 (en) * 1997-04-17 2002-06-20 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US20050065320A1 (en) * 2001-09-06 2005-03-24 Frederic Bedin Mutated env gene, mutated env glycoprotein and the use thereof
US20060281673A1 (en) * 2003-02-11 2006-12-14 Marius Clore Novel peptide inhibitor of hiv fusion that disrupts the internal trimeric coiled-coil of gp41

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020077284A1 (en) * 1997-04-17 2002-06-20 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US20050065320A1 (en) * 2001-09-06 2005-03-24 Frederic Bedin Mutated env gene, mutated env glycoprotein and the use thereof
US20060281673A1 (en) * 2003-02-11 2006-12-14 Marius Clore Novel peptide inhibitor of hiv fusion that disrupts the internal trimeric coiled-coil of gp41

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUN JU PARK ET AL., JOURNAL OF VIROLOGY, vol. 72, no. 9, September 1998 (1998-09-01), pages 7099 - 7107 *
SIMON BEDDOWS ET AL., VIROLOGY, vol. 337, no. 1, June 2005 (2005-06-01), pages 136 - 148 *

Also Published As

Publication number Publication date
WO2010040136A4 (en) 2010-09-02
WO2010040136A2 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
WO2011032161A8 (en) Vaccines directed to langerhans cells
EP4509189A3 (en) Anti-fcrn antibodies
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
WO2012051211A3 (en) Antigen delivery platforms
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
EP3786183A3 (en) Antigen binding constructs to cd3
WO2012032181A3 (en) Antibody derivatives
WO2010027818A3 (en) Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
WO2013142324A8 (en) Neutralizing antibodies to hiv-1 and their use
HK1216894A1 (en) Multivalent binding protein compositions
IL228991A0 (en) Prostate-specific membrane antigen binding proteins and related compositions and methods
IL221205A0 (en) Antibody drug conjugates (adc) that bind to 161p2f10b proteins, compositions comprising the same and uses thereof
WO2010136483A3 (en) Antigen-binding proteins
WO2013006688A3 (en) N-terminal deleted gp120 immunogens
IL266452B (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof
WO2012047267A3 (en) Polyvalent immunogen
WO2014131019A3 (en) Her-1, her-3 and igf-1r compositions and uses thereof
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
EP2928492A4 (en) Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies
WO2015051379A3 (en) Dual specific binding proteins directed against immune cell receptors and tlr signaling autoantigens
WO2013122544A3 (en) IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
WO2010040136A3 (en) Selection of hiv vaccine antigens by use of intrapatient sequence variation to identify mutations in the hiv envelope glycoprotein that affect the binding of broadly neutralizing antibodies
WO2011100508A3 (en) Methods and compositions related to glycoprotein-immunoglobulin fusions
WO2014033158A3 (en) Pcsk9 peptide vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09818620

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09818620

Country of ref document: EP

Kind code of ref document: A2